Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025
Reuters
Oct 07
<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025
Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus $(HDV)$ infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.